Influence of non-alcoholic fatty liver disease on cardiovascular disease;Influencia de la enfermedad por hígado graso no alcohólico en la enfermedad cardiovascular

Gastroenterologia y Hepatologia

Volumn 35, Issue 8, 2012, Pages 585-593

  Ampuero, Javier ^a   Romero Gómez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Cardiovascular disease; Intima media thickening; Non alcoholic fatty acid disease (NAFLD); Non alcoholic steatohepatitis (NASH); Subclinical atherosclerosis

Indexed keywords

ALCOHOL CONSUMPTION; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROMATOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER;

APOLIPOPROTEIN C-III; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL, LDL; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FATTY LIVER; HUMANS; HYPERHOMOCYSTEINEMIA; INSULIN RESISTANCE; LIPASE; MEMBRANE PROTEINS; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; SMOKING; TRIGLYCERIDES;

EID: 84866492343     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2012.02.005     Document Type: Article

References (49)

1. Kotronen A., Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:27-38.
2. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in nonalcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia 2008, 51:1947-1953.
3. Sanyal A.J., Banas C., Sargeant C., Luketic V.A., Sterling R.K., Stravitz R.T., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006, 43:682-689.
4. Mitra S., Deshmukh A., Sachdeva R., Lu J., Mehta J.L. Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy. Am J Med Sci 2011, 342:135-142.
5. Kim H.C., Kim D., Huh K.B. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009, 204:521-525.
6. Bos D., Ikram M.A., Elias-Smale S.E. Calcification in major vessel beds relates to vascular brain disease. Arterioscler Thromb Vasc Biol 2011, 31:2331-2337.
7. Akamatsu D., Sato A., Goto H., Watanabe T., Hashimoto M., Shimizu T., et al. Nitroglycerin-mediated vasodilatation of the brachial artery may predict long-term cardiovascular events irrespective of the presence of atherosclerotic disease. J Atheroscler Thromb 2010, 17:1266-1274.
8. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007, 25:1105-1187.
9. Lind L. Circulating Markers of Inflammation and Atherosclerosis. Atherosclerosis 2003, 169:203-214.
10. Amar J., Fauvel J., Drouet L., Ruidavets J.B., Perret B., Chamontin B., et al. Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J Hypertens 2006, 24:1083-1088.
11. Haddy N., Sass C., Droesch S. IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003, 170:277-283.
12. Targher G., Chonchol M., Miele L., Zoppini G., Pichiri I., Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009, 35:277-287.
13. Leonarduzzi G., Gamba P., Gargiulo S., Biasi F., Poli G. Inflammation-related gene expression by lipid oxidation-derived products in the progression of atherosclerosis. Free Radic Biol Med 2012, 52:19-34.
14. Shamseddeen H., Getty J.Z., Hamdallah I.N. Epidemiology and economic impact of obesity and type 2 diabetes. Surg Clin North Am 2011, 91:1163-1172.
15. Erbel R., Lehmann N., Möhlenkamp S. Subclinical Coronary Atherosclerosis Predicts Cardiovascular Risk in Different Stages of Hypertension: Result of the Heinz Nixdorf Recall Study. Hypertension 2012, 59:44-53.
16. Hsieh P.S., Hsieh Y.J. Impact of liver diseases on the development of type 2 diabetes mellitus. World J Gastroenterol 2011, 17:5240-5245.
17. Day C.P., James O.F. Steatohepatitis: a tale of two " hits" ?. Gastroenterology 1998, 114:842-845.
18. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
19. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363:1341-1350.
20. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
21. Clouston A., Powell E. Nonalcoholic fatty liver disease: Is all the fat bad?. Intern Med J 2004, 34:187-191.
22. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
23. Tamura S., Shimomura I. Contribution of adipose tissue and de novo lipogenesis to non alcoholic fatty liver disease. J Clin Invest 2005, 115:1139-1142.
24. Frederico M.J., Vitto M.F., Cesconetto P.A., Engelmann J., De Souza D.R., Luz G., et al. Short-term inhibition of SREBP-1c expression reverses diet-induced non-alcoholic fatty liver disease in mice. Scand J Gastroenterol 2011, 46:1381-1388.
25. Cohen J., Horton J., Hobbs H. Human fatty liver disease: old questions and new insights. Science 2011, 232.
26. Aubert J., Begriche K., Knockaert L., Robin M.A., Fromenty B. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol 2011, 35:630-637.
27. Dixon J.B, Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121:91-100.
28. Romero-Gómez M. APOC3 polymorphisms and non-alcoholic fatty liver disease: Resolving some doubts and raising others. J Hepatology 2011, 55:1184-1186.
29. Petersen K.F., Dufour S., Hariri A., Nelson-Williams C., Foo J.N., Zhang X.M., et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010, 362:1082-1089.
30. Lee H.-Y, Birkenfeld A.L., Jornayvaz F.R., Jurczak M.J., Kanda S., Popov V., et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 2011, 54:1650-1660.
31. Valenti L., Nobili V., Al-Serri A., Rametta R., Leathart J.B., Zappa M.A., et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol 2011, 55:1409-1414.
32. Olivieri O., Martinelli N., Girelli D. Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation. J Thromb Haemost 2010, 8:463-471.
33. Scheffer P.G., Teerlink T., Dekker J.M. Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study. Clin Chem 2008, 54:1325-1330.
34. Mendivil C.O., Rimm E.B., Furtado J., Chiuve S.E., Sacks F.M. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 2011, 124:2065-2072.
35. Abd El-Aziz T.A., Mohamed R.H., Hashem R.M. Association of lipoprotein lipase and apolipoprotein C-III genes polymorphism with acute myocardial infarction in diabetic patients. Mol Cell Biochem 2011, 354:141-150.
36. Dubuquoy C., Robichon C., Lasnier F., Langlois C., Dugail I., Foufelle F., et al. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. J Hepatol 2011, 55:145-153.
37. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461-1465.
38. Wagenknecht L.E., Palmer N.D., Bowden D.W., Rotter J.I., Norris J.M., Ziegler J., et al. Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study. Liver Int 2011, 31:412-416.
39. Trépo E., Pradat P., Potthoff A., Momozawa Y., Quertinmont E., Gustot T., et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011, 54:60-69.
40. Trépo E., Gustot T., Degré D., Lemmers A., Verset L., Demetter P., et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol 2011, 55:906-912.
41. Petit J.M., Guiu B., Masson D. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes. Liver International 2011, 31:1332-1336.
42. Mohammadi A., Habibpour H., Ghasemi-Rad M. Evaluation of carotid intima-media thicknessand flow-mediated dilatation in middle-agedpatients with nonalcoholic fatty liver disease. Vasc Health Risk Manag 2011, 7:661-665.
43. Mohammadi A, Bazazi A, Ghasemi-Rad M. Evaluation of atherosclerotic findings in patients with nonalcoholic fatty liver disease. Int J Gen Med. 2011;4:717-22.
44. Poanta L., Albu A., Fodor D. Association between fatty liver disease and carotid atherosclerosis in patients with uncomplicated type 2 diabetes mellitus. Med Ultrason 2011, 13:215-219.
45. McKimmie R.L., Daniel K.R., Carr J.J., Bowden D.W., Freedman B.I., Register T.C., et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 2008, 103:3029-3035.
46. Agarwal AK, Jain V, Singla S, Baruah BP, Arya V, Yadav R, et al. Prevalence of Non-Alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes. J AssocPhysicians India. 2011;59:351-4.
47. Lazo M., Hernaez R., Bonekamp S., Kamel I.R., Brancati F.L., Guallar E., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011, 343:6891.
48. Bhala N., Angulo P., Poorten D., Lee E., Hui J.M., Saracco G., et al. The Natural History of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis or Cirrhosis: An International Collaborative Study. Hepatology 2011, 54:1208-1216.
49. Wong V., Wong G., Yip G.W., Lo A.O., Limquiaco J., Chu W.C., et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011, 60:1721-1727.